CN114586779B - 抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒pvc热收缩标签膜及其制备方法 - Google Patents
抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒pvc热收缩标签膜及其制备方法 Download PDFInfo
- Publication number
- CN114586779B CN114586779B CN202210358111.4A CN202210358111A CN114586779B CN 114586779 B CN114586779 B CN 114586779B CN 202210358111 A CN202210358111 A CN 202210358111A CN 114586779 B CN114586779 B CN 114586779B
- Authority
- CN
- China
- Prior art keywords
- antiviral
- antibacterial
- traditional chinese
- chinese medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 78
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003094 microcapsule Substances 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 39
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims abstract description 28
- 239000004926 polymethyl methacrylate Substances 0.000 claims abstract description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims abstract description 19
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims abstract description 19
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 18
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 11
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 11
- 230000008878 coupling Effects 0.000 claims abstract description 6
- 238000010168 coupling process Methods 0.000 claims abstract description 6
- 238000005859 coupling reaction Methods 0.000 claims abstract description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 39
- 238000002156 mixing Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000003444 phase transfer catalyst Substances 0.000 claims description 14
- 239000006087 Silane Coupling Agent Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000011812 mixed powder Substances 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000010096 film blowing Methods 0.000 claims description 6
- 238000007670 refining Methods 0.000 claims description 6
- 239000006057 Non-nutritive feed additive Substances 0.000 claims description 5
- 238000007664 blowing Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000012760 heat stabilizer Substances 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 4
- 239000012744 reinforcing agent Substances 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- HLMNIITWIKSHIS-UHFFFAOYSA-N 2,2-diethoxycyclohexan-1-one Chemical group CCOC1(OCC)CCCCC1=O HLMNIITWIKSHIS-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 14
- 239000013078 crystal Substances 0.000 abstract description 10
- 239000002775 capsule Substances 0.000 abstract description 9
- 238000012545 processing Methods 0.000 abstract description 5
- 239000003223 protective agent Substances 0.000 abstract description 5
- 238000010008 shearing Methods 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000000227 grinding Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000002861 polymer material Substances 0.000 abstract description 2
- 230000000717 retained effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 235000013350 formula milk Nutrition 0.000 description 10
- 229960003390 magnesium sulfate Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 241000205585 Aquilegia canadensis Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- PIZHFBODNLEQBL-UHFFFAOYSA-N 2,2-diethoxy-1-phenylethanone Chemical compound CCOC(OCC)C(=O)C1=CC=CC=C1 PIZHFBODNLEQBL-UHFFFAOYSA-N 0.000 description 3
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 3
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000000071 blow moulding Methods 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000020610 powder formula Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004605 External Lubricant Substances 0.000 description 1
- 239000004610 Internal Lubricant Substances 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000206469 Pulsatilla Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940076230 magnesium sulfate monohydrate Drugs 0.000 description 1
- QSOMFNQEXNFPNU-UHFFFAOYSA-L magnesium;hydrogen sulfate;hydroxide;hydrate Chemical compound O.O.[Mg+2].[O-]S([O-])(=O)=O QSOMFNQEXNFPNU-UHFFFAOYSA-L 0.000 description 1
- LFCFXZHKDRJMNS-UHFFFAOYSA-L magnesium;sulfate;hydrate Chemical compound O.[Mg+2].[O-]S([O-])(=O)=O LFCFXZHKDRJMNS-UHFFFAOYSA-L 0.000 description 1
- LVCQAASWWXWFTQ-UHFFFAOYSA-L magnesium;sulfate;pentahydrate Chemical compound O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O LVCQAASWWXWFTQ-UHFFFAOYSA-L 0.000 description 1
- QIGOZTHDQZFDPY-UHFFFAOYSA-L magnesium;sulfate;trihydrate Chemical compound O.O.O.[Mg+2].[O-]S([O-])(=O)=O QIGOZTHDQZFDPY-UHFFFAOYSA-L 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
- A01N25/28—Microcapsules or nanocapsules
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/06—Aluminium; Calcium; Magnesium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2327/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Derivatives of such polymers
- C08J2327/02—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Derivatives of such polymers not modified by chemical after-treatment
- C08J2327/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Derivatives of such polymers not modified by chemical after-treatment containing chlorine atoms
- C08J2327/06—Homopolymers or copolymers of vinyl chloride
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/30—Sulfur-, selenium- or tellurium-containing compounds
- C08K2003/3045—Sulfates
- C08K2003/3063—Magnesium sulfate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
- C08K5/0058—Biocides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/04—Ingredients treated with organic substances
- C08K9/06—Ingredients treated with organic substances with silicon-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/10—Encapsulated ingredients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Pest Control & Pesticides (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于高分子材料技术领域，具体涉及抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒PVC热收缩标签膜及其制备方法。本发明在中药材粉体内加入一定量的七水硫酸镁晶体研磨粉，混合均匀，并进行偶联处理，在PVC热收缩标签膜加工温度范围内，硫酸镁晶体能全程很好发挥高温保护剂作用。此外，通过光引发聚合技术为混有七水硫酸镁的中药粉体低温制备一层PMMA保护胶囊。在七水硫酸镁高温保护剂和PMMA胶囊吸收和消耗剪切力的双重保护作用下，中药粉剂能在PVC热收缩标签膜加工制作过程中，不受或少受破坏，最大限度保留其药效，在标签使用过程中更好发挥抑菌抗病毒功效。
Description
技术领域
本发明属于高分子材料技术领域，具体涉及抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒PVC热收缩标签膜及其制备方法。
背景技术
由于PVC热收缩标签可以赋予瓶装饮料和纯净水360°标签设计，通过印刷精美图案和绚丽色彩，形成较强视觉冲击的包装宣传效果，凸显商品在超市货架上的完美形象和吸引力，便于品牌差异化设计和市场营销。PVC材料因其良好综合性能和优异的性价比，成为当前瓶装饮品的主要收缩标签形式之一。热收缩标签还会直接与消费者接触，使用者接触热收缩标签时，手上的细菌、病毒会因直接接触，部分转移到饮料瓶外的标签上。所以，瓶装饮料饮用过程中，手上细菌更易污染或转移到收缩标签上，从而带来一定的安全隐患和风险。另外，饮品在货架摆放、交易扫码、相互传递等过程中，细菌和病毒也会对收缩标签、瓶盖以及部分裸露瓶体造成污染。
如果标签具有抑菌抗病毒功能，可以有效减少瓶装饮品上细菌和病毒的存留活体数量，提高瓶装饮品饮用的安全性。中医药是中华民族的传统瑰宝，中药是其重要组成部分，中药是中医预防治疗疾病所使用的独特药物，也是中医区别于其他医学的重要标志。中药主要由植物药(根、茎、叶、果)和矿物药组成。因植物药占中药的大多数，所以中药也称中草药。中药应用理论独特，应用形式多种多样，有用药物加水煎熟后去渣留汁而成的汤剂，有研磨成粉末状的粉剂，还有丸剂、膏剂、酒剂、片剂、冲剂等。
加强常用品的抑菌抗病毒功效，可以更有效地预防病毒和致病菌的传播，借助中药特性，设计一款综合杀菌、抗病毒的外用中药粉剂配方，添加到PVC热收缩标签膜中，赋予标签抑菌抗病毒功能，提高饮品使用的卫生安全性。PVC热收缩标签膜加工制作时，需要将PVC配方中各种成分通过捏合(高速、高温混合)、挤出塑化成型(高剪切、高温熔融塑型)制成具有热收缩功能的薄膜。在这个过程中，添加到配方中的中药粉剂会因高温高剪切作用，产生碳化、变性等反应，会导致其药性丧失，作用失效。因此，如何保护中药在高温高剪切作用下药性不被破坏，是需要重点解决的技术难题。
发明内容
针对上述现有技术的不足，本发明提供了抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒PVC热收缩标签膜及其制备方法，目的是为了解决杀菌抗病毒的外用中药粉剂添加到PVC热收缩标签膜中，中药粉剂会因高温高剪切作用，产生碳化、变性等反应，会导致其药性丧失，作用失效的技术问题。
本发明提供的第一个技术方案为抑菌抗病毒中药微胶囊的制备方法，具体技术方案如下：
抑菌抗病毒中药微胶囊的制备方法，将中药粉体和七水硫酸镁混合并偶联处理后，采用紫外光引发甲基丙烯酸甲酯聚合反应在制备包裹中药粉体PMMA囊壳，获得抑菌抗病毒中药微胶囊。
在某些实施方式中，包括如下步骤：
S1，中药材粉碎并与七水硫酸镁混合，获得混合粉料；
S2，用硅烷偶联剂溶液对步骤S1中的混合粉料进行偶联处理，获得内核混合物；
S3，甲基丙烯酸甲酯经过精制处理后，与聚甲基丙烯酸甲酯、光引发剂和相转移催化剂混合，获得外壳混合物；
S4，将步骤S2的内核混合物与步骤S3中的壳混合物进行混合，紫外光引发聚合反应，获得抑菌抗病毒中药微胶囊。
进一步，步骤S1中，所述中药材包括金银花、野菊花、蒲公英和薄荷，所述七水硫酸镁质量为所述中药材质量的5-8％。
进一步，步骤S2中，所述硅烷偶联剂溶液是用甲基丙烯酸甲酯和去离子水混合配制而成，硅烷偶联剂含量为0.8-1.0％，甲基丙烯酸和去离子水质量比为80-85:15-20；所述硅烷偶联剂溶液的用量为所述混合粉料质量的0.8-1.2％。
进一步，步骤S3中，所述甲基丙烯酸甲酯精制处理如下：等体积的甲基丙烯酸甲酯和10％NaOH溶液混合，剧烈搅拌，静置分层，弃去下层红色的阻聚剂和NaOH溶液，重复操作数次，直至溶液变成无色为止，用蒸馏水洗涤至中性，加入硫酸镁，静置半小时，过滤后进行减压蒸馏，收集馏分，获得精制甲基丙烯酸甲酯；
甲基丙烯酸甲酯与聚甲基丙烯酸甲酯的质量比为30-35:65-70；
光引发剂的用量为甲基丙烯酸甲酯质量的1.0-1.5％，光引发剂为2,2-二乙氧基-1-苯己酮；
相转移催化剂用量为甲基丙烯酸甲酯质量的0.2-0.5％，相转移催化剂为含氯的季铵盐类相转移催化剂。
进一步，步骤S4中，内核混合物与外壳混合物的质量份比例为75-80:20-25；
聚合反应中，紫外线辐射强度：120x120μw/cm2，紫外线波长：365nm，功率：1800w，外壳混合物分两次与内核混合物搅拌以及紫外线照射，每次搅拌时间为5-10分钟，每次紫外照射时间为3-5分钟。
本发明提供的第二个技术方案为抑菌抗病毒中药微胶囊，具体技术方案如下：
抑菌抗病毒中药微胶囊，利用第一个技术方案的方法制备获得的PMMA胶囊保护的中药粉体微粒。
本发明提供的第三个技术方案为抑菌抗病毒PVC热收缩标签膜的制备方法，具体技术方案如下：
抑菌抗病毒PVC热收缩标签膜的制备方法，将PVC树脂、热稳定剂、增塑剂、加工助剂、增强剂、内润滑剂、外润滑剂和抑菌抗病毒助剂混合，并经过挤出机塑化、吹膜机头成型、风环冷却、第一膜泡、二次加热、二次吹胀、冷却定型，抑菌抗病毒PVC热收缩标签膜，所述抑菌抗病毒助剂为第二个技术方案的抑菌抗病毒中药微胶囊。
在某些实施方式中，按质量份计，PVC树脂100份、热稳定剂2份、增塑剂4.5份、加工助剂2份、增强剂4份、内润滑剂1.2份、外润滑剂0.8份和抑菌抗病毒助剂3-5份。
本发明提供的第四个技术方案为抑菌抗病毒PVC热收缩标签膜，具体技术方案如下：
抑菌抗病毒PVC热收缩标签膜，利用第三个技术方案的方法制备的具有抑菌抗病毒性能的PVC热收缩标签膜。
本发明具有以下有益效果：在中药材粉体内加入一定量的七水硫酸镁晶体研磨粉，混合均匀，并进行偶联处理。七水硫酸镁是一种白色结晶状固体，含有7个结晶水，不同温度下脱去结晶水的数量不同，硫酸镁脱结晶水为吸热反应，同时脱下来的水分挥发过程还能带走一部分热量，在高温条件下，硫酸镁靠脱结晶水可以实现局面降温，较好地保护和它混合在一起的中药粉末免受高温危害。七水硫酸镁在60℃时，脱去一个结晶水成六水硫酸镁，在103℃时形成五水硫酸镁，在108℃时形成三水硫酸镁，在127℃时形成二水硫酸镁，在149℃时形成一水硫酸镁，在285℃才完全脱除结晶水，形成无水硫酸镁。而PVC热收缩标签膜成型过程中最高加工温度一般情况下小于230℃，因此，在PVC热收缩标签膜加工温度范围内，硫酸镁晶体能全程很好发挥高温保护剂作用。此外，硫酸镁还具有消炎去肿之外用药功效，也能对中药抑菌抗病毒提供一定帮助。
通过光引发聚合技术为混有七水硫酸镁的中药粉体低温(避免高温反应条件下硫酸镁丧失部分结晶水，低温保护作用下降)制备一层PMMA保护胶囊。PMMA与PVC溶解度参数相近，与PVC间具有良好的相容性，便于将中药粉剂均匀分散到PVC体系中，最大限度的发挥其效能。同时，中药粉体外面包裹着PMMA保护层，在受到剪切力作用时，PMMA会先吸收和消耗掉大部分能量，减少或避免剪切力对内部中药粉体的冲击和破坏，为中药粉体提供有力的力学保护。
因此，在七水硫酸镁高温保护剂和PMMA胶囊吸收和消耗剪切力的双重保护作用下，中药粉剂能在PVC热收缩标签膜加工制作过程中，不受或少受破坏，最大限度保留其药效，在标签使用过程中更好发挥抑菌抗病毒功效。
附图说明
图1是本发明抑菌抗病毒中药微胶囊的制备方法的流程图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白，以下结合具体实施例，并参照附图1，对本发明进一步详细说明。
一、抑菌抗病毒中药微胶囊制备
1、抑菌抗病毒中药配方
(1)中药组成及相关作用(功效)
金银花：自古被誉为清热解毒良药。具有抗病原微生物、抗毒、抗炎、解热、促进炎细胞吞噬功能等作用，体外实验表明，金银花煎剂及醇浸液对金黄色葡萄球菌、白色葡萄球菌、溶血性链球菌、肺炎杆菌、脑膜炎双球菌、伤寒杆菌、副伤寒杆菌、大肠杆菌、痢疾杆菌、变形杆菌、百日咳杆菌、铜绿假单胞菌、结核杆菌、霍乱弧菌等多种革兰阳性和阴性菌均有一定的抑制作用。
野菊花：具有散风清热、清肝明目、解毒消炎、抑菌、抗病原微生物等作用；具有增强吞噬细胞吞噬功能；能抑制金黄色葡萄菌血浆凝固酶形成。煎剂体外实验表明具有一定的广谱抑菌作用。
白头翁：抗菌有效成分为原白头翁素和白头翁素，具有抗菌、抗阿米巴原虫、抗病原体、镇静、镇痛等作用。
蒲公英：具有清热解毒、抗菌利尿、护肝明目等功效；其还具有预防湿疹、美容养颜、抗肿瘤、消炎、抗病原微生物等作用。注射液在试管内对金黄色葡萄球菌耐药菌株、溶血性链球菌有较强的杀菌作用，对肺炎双球菌、脑膜炎球菌、白喉杆菌、绿脓杆菌、变形杆菌、痢疾杆菌、伤寒杆菌及卡他球菌亦有一定的杀菌作用。
薄荷：具有消炎、止痛、止痒作用；对革兰氏阻性、革兰氏阴性球菌、杆菌及多种病毒有一定的抑制作用。
表1中药配方组成(质量份)
| 金银花 | 野菊花 | 白头翁 | 蒲公英 | 薄荷 |
| 35 | 25 | 15 | 15 | 10 |
(2)中药粉碎处理
为更好发挥药效，也便于将其添加到PVC配方体系，按照配比准确称取各种(干燥)中药材，简单混合，用3000目筛网的万能中药粉碎机粉碎，将中药材粉碎成5μm左右的粉末。
2、中药粉体与七水硫酸镁混合处理(内核混合物)
(1)七水硫酸镁晶体处理
为高温保护剂，选用医药级的七水硫酸镁，低温研磨，使其与中药粉粒径相当，。
(2)混合
称取中药材重量的5-8％研磨好的七水硫酸镁，加入粉末中，混合均匀。
(3)偶联处理
偶联剂配置：用甲基丙烯酸甲酯和去离子水配置硅烷偶联剂溶液，硅烷偶联剂含量为0.8-1.0％，硅烷偶联剂可选用KH-550、Kh-560、KH-570、KH-590、KH-602等品种。溶液中甲基丙烯酸和去离子水质量比为80-85:15-20。
量取中药粉体+七水硫酸镁质量的0.8-1.2％硅烷偶联剂溶液，喷洒到混合机中混合着的中药粉体和七水硫酸镁上，混合均匀备用。
3、PMMA微胶囊制备(外壳混合物)
采用紫外光引发MMA(甲基丙烯酸甲酯)聚合反应制备PMMA(聚甲基丙烯酸甲酯)囊壳。为了提高囊壳成型反应速率，增加反应液粘度，在MMA单体中加入一定比例的PMMA聚合物。同时对参与反应的MMA进行精制处理，去除其中的阻聚剂对苯二酚，以防止光引发聚合时，阻聚剂降低引发效率，降低反应的转化率，使PMMA聚合物分子量偏小。
(1)MMA精制处理
在500mL的分液漏斗中加入150mLMMA，并加入等体积的10％NaOH溶液，剧烈搅拌，静置分层，弃去下层红色的阻聚剂和NaOH溶液，重复操作数次，直至溶液变成无色为止。然后用蒸馏水洗涤至中性，加入3g硫酸镁，静置半小时，过滤。将过滤后的单体MMA移到250mL三口烧瓶中减压蒸馏，三口烧瓶连接好抽真空系统和冷凝装置，使三口烧瓶内真空压力稳定在1333Pa，温度在60℃的条件下，收集馏分，获得不含对苯二酚的精制MMA。低温保存，备用。
(2)MMA和PMMA混合
MMA和PMMA质量比为30-35:65-70。
向500mL三口瓶中加入一定比例的精制MMA、PMMA(平均聚合度n＝1000-1200)，在回流中逐渐升温至60℃，直至PMMA全部溶解于MMA中。
(3)配置光引发溶液
向溶解了PMMA的MMA溶液中添加一定量的光引发剂DEAP和含氯的季铵盐类相转移催化剂。混合均匀。搅拌，备用。
光引发剂DEAP，化学名为2,2-二乙氧基-1-苯己酮。为淡黄色透明液体，是一种高效光引发剂，与低聚物具较好的相容性。吸收波长210n，250nm。其用量为MMA质量的1.0-1.5％。可直接添加。
含氯的季铵盐类相转移催化剂可以选用十二烷基三甲基氯化铵、苄基三乙基氯化铵、十四烷基三甲基氯化铵、三辛基甲基氯化铵等。添加量为MMA质量的0.2-0.5％。使用时先用少量乙醇将其溶解，然后再将乙醇溶液投加到MMA/PMMA溶液中。
相转移催化剂的存在，可以与水相中的离子所结合，并利用自身对有机溶剂的亲和性，将水相中的反应物转移到有机相中，促使发生反应。相转移催化剂的加入可以加速光引发聚合反应，使该自由基聚合反应进行的更快更彻底，便于在中药粉体和硫酸镁晶体混合物颗粒外层快速聚合形成保护胶囊。
4、中药粉体胶囊制备
反应物组成(质量份)比例如下：内核混合物：外壳混合物＝75-80:20-25。紫外光引发聚合反应，采用365紫外灯管，UV辐射强度：120x120μw/cm2，紫外线波长：365nm，总功率：1800w。
制备聚合反应过程：
①开启紫外光反应器搅拌装置，转速为30转/分，将计量好的一定量中内核混合物添加到搅拌器中，粉体在反应器内不停翻转。
②按照配方比例称取外壳混合物，分成两半，分两次加入。分次加入是为使MMA/PMMA反应更快更充分(较短时间内获得更多光能)，便于在中药粉体外面形成较致密的胶囊保护壳。
③先取一半外壳混合物加入到搅拌着内核混合物的反应器中，搅拌5-10分钟，使两者充分混合均匀。继续搅拌，并开启反应器的紫外光灯，在紫外光照射下，搅拌反应3-5分钟。然后关闭紫外灯，再将剩余一半溶液加入到反应容器中，搅拌5-10分钟混合均匀，再打开紫外光灯，紫外光照射下搅拌反应3-5分钟，结束反应。
④反应结束后，将反应物从反应器的侧下部出口放出，用四氢呋喃洗涤，去除未发生反应的MMA单体，然后移至真空烘箱，60℃干燥2-3小时，获得PMMA胶囊保护的中药粉体微粒，即抑菌抗病毒中药微胶囊。
二、中药抑菌抗病毒PVC热收缩标签膜制备
1、配方
在普通透明PVC热收缩标签膜配方基础上，添加PMMA胶囊保护的中药粉体微粒(简称：PMMA-中药粉体微粒)，对配方中润滑剂配比进行相应微调，其它组分配比保持不变。
表2抑菌抗病毒PVC热收缩标签膜和普通透明PVC热收缩标签膜的配方
表3实施例1-4抑菌抗病毒PVC热收缩标签膜配方组成
在具体的实施例(实施例1-4)中，硅烷偶联剂溶液的用量为混合粉料(中药粉体+七水硫酸镁)质量的1.0％，光引发剂DEAP用量为MMA质量的1.0％。相转移催化剂为十二烷基三甲基氯化铵，添加量为MMA质量的0.3％。
2、捏合工艺
采用高速混合机+冷却(低速)混合机搭配的形式，将配方中各组分混合为均一的干混料。
混合过程中加料顺序
①高速混合机转动过程中投加PVC树脂、稳定剂、增塑剂；
②高速混合机温度升高到75-80℃时，投加增强剂、加工助剂、内润滑剂；
③高速混合机温度升高到95-100℃时，投加外润滑剂；
④高速混合机温度升高到125℃左右时，将混合料放入冷却混合机中搅拌冷却；
⑤冷却混合机温度到70-75℃时，投加抑菌抗病毒助剂，继续搅拌混合冷却；
⑥冷却混合机温度到45℃以下时出料，备用。
3、吹塑成型
采用与普通PVC热收缩标签膜相同的设备及工艺吹塑成型。
吹膜机组为机头旋转、风环冷却，一泡和二泡均为上吹成型方式，二次吹胀前采用水浴加热。
工艺流程：干混料—挤出机塑化—吹膜机头成型—风环冷却—第一膜泡—二次加热—二次吹胀—冷却定型—卷取—半成品—分切—包装—成品。
挤出吹膜：
设备：单螺杆挤出机，螺杆直径70mm，螺杆长径比26.5:1，压缩比2.8:1。
吹膜模具口模直径130mm，口模间隙0.9mm，双风口风环。
挤出机温度：140-150℃，150-160℃，160-170℃，175-185℃，170-180℃。连接段温度：175-185℃。模具温度:185-195℃，190-200℃。水箱加热温度76-79℃。
4、中药抑菌抗病毒PVC热收缩标签膜相关性能检测
(1)热收缩标签薄膜常规性能对比
表4热收缩标签薄膜常规性能结果
由表4可知，本发明提供的抑菌抗病毒PVC热收缩标签膜的收缩率、拉伸强度、断裂伸长率与普通PVC热收缩标签膜能够保证一致，由于中药材本身具有一定的颜色和遮光性，因此对PVC热收缩标签膜透光率产生一定的影响。
(2)抗菌性测试及结果
抗菌率测试：按照GB/T31402-2015《塑料塑料表面抗菌性能试验方法》进行相关测试。
检测用菌为大肠杆菌CGMCC1.2463(等同于ATCC 8739)和金黄色葡萄球菌CGMCC1.2910(等同于ATCC6538P)。将抑菌抗病毒PVC热收缩标签膜、普通PVC热收缩标签膜(作为空白对比样品)裁切成50mm×50mm试样，各准备3片，并用质量分数为70％乙醇溶液消毒处理并晾干。将菌种用1/500营养肉汤稀释成细菌浓度为9.0x105CFU/mL的菌悬液备用。用移液管取0.4mL的菌悬液滴在试样表面，用0.05～0.10mm厚的聚乙烯薄膜(尺寸40mm×40mm)覆于其上，轻压使菌悬液在试样与薄膜间形成均匀的液膜。在(35±1)℃，相对湿度不小于90％的条件下培养24h。用10mL SCDLP肉汤培养基清洗菌液，并用磷酸盐缓冲生理盐水稀释成适当的浓度梯度，将试样上的回收液及10倍稀释液各取1mL，分别放入无菌培养皿中，每个培养皿中注入15mL平板计数琼脂，轻轻搅拌或摇匀以分散细菌。待培养基凝固后翻转培养皿，于(35±1)℃培养24h和48h，观察结果。
表5大肠杆菌抗菌性测试结果
表6金黄色葡萄球菌抗菌性测试结果
由表5-6可见，抑菌抗病毒PVC热收缩标签膜对大肠杆菌、金黄色葡萄球菌24h和48h抗菌率均大于90％，具有抗菌性。且随着配方中PMMA-中药粉体微粒用量增加抗菌性能增强。
(3)抗病毒性能测试及结果
由于塑料制品没有抗病毒相关检验标准，故参照团体标准T/GDTL011-2020《抗菌、抗病毒涂料》中相关抗病毒测试内容对中药抑菌抗病毒PVC热收缩标签膜进行抗病毒测试分析。
病毒和宿主选用：甲型流感病毒(H3N2)，宿主细胞MDCK细胞；肠道病毒EV71，宿主细胞Vero细胞。
试样：规格50mmx50mm，用PVC热收标签膜直接裁取，表面用70％乙醇溶液消毒处理并晾干。每个实施例每项病毒测试选取3片试样，对照样(普通PVC热收缩标签膜)视测试需要选取6片或3片试样。分别单独放入无菌培养皿中，测试面朝上。
测试操作步骤按照T/GDTL011-2020附录A中抗病毒涂料的试验方法进行，获取蚀斑法病毒滴度抗病毒测试结果。
分别用甲型流感病毒(H3N2)和肠道病毒EV71进行抗病毒性能和抗病毒耐久性能测试。
表7抗病毒性能测试一结果
表8抗病毒性能测试二结果
表9抗病毒耐久性能测试一结果
表10抗病毒耐久性能测试二结果
由表7-10可见，中药抑菌抗病毒PVC热收缩标签膜对甲型流感病毒(H3N2)和肠道病毒EV71均具有较好的抗病毒性能和抗病毒耐久性能，且随着配方中PMMA-中药粉体微粒用量增加抗病毒性能增强。
综上所述，中药抑菌抗病毒PVC热收缩标签膜具有抗菌抗病毒的功能，本发明很好地解决了“保护中药在高温高剪切作用下药性不被破坏”的技术难题。
上述仅本发明较佳可行实施例，并非是对本发明的限制，本发明也并不限于上述举例，本技术领域的技术人员，在本发明的实质范围内，所作出的变化、改型、添加或替换，也应属于本发明的保护范围。
Claims (5)
1.抑菌抗病毒中药微胶囊的制备方法，其特征在于，包括如下步骤：
S1，中药材粉碎并与七水硫酸镁混合，获得混合粉料；
S2，用硅烷偶联剂溶液对步骤S1中的混合粉料进行偶联处理，获得内核混合物；所述硅烷偶联剂溶液是用甲基丙烯酸甲酯和去离子水混合配制而成，硅烷偶联剂含量为0.8-1.0％，甲基丙烯酸和去离子水质量比为80-85:15-20；所述硅烷偶联剂溶液的用量为所述混合粉料质量的0.8-1.2％；
S3，甲基丙烯酸甲酯经过精制处理后，与聚甲基丙烯酸甲酯、光引发剂和相转移催化剂混合，获得外壳混合物；所述甲基丙烯酸甲酯精制处理如下：等体积的甲基丙烯酸甲酯和10％NaOH溶液混合，剧烈搅拌，静置分层，弃去下层红色的阻聚剂和NaOH溶液，重复操作数次，直至溶液变成无色为止，用蒸馏水洗涤至中性，加入硫酸镁，静置半小时，过滤后进行减压蒸馏，收集馏分，获得精制甲基丙烯酸甲酯；甲基丙烯酸甲酯与聚甲基丙烯酸甲酯的质量比为30-35:65-70；光引发剂的用量为甲基丙烯酸甲酯质量的1.0-1.5％，光引发剂为2,2-二乙氧基-1-苯己酮；相转移催化剂用量为甲基丙烯酸甲酯质量的0.2-0.5％，相转移催化剂为含氯的季铵盐类相转移催化剂；
S4，将步骤S2的内核混合物与步骤S3中的壳混合物按照质量份比例为75-80:20-25进行混合，紫外光引发聚合反应，紫外线辐射强度：120x120μw/cm2，紫外线波长：365nm，功率：1800w，外壳混合物分两次与内核混合物搅拌以及紫外线照射，每次搅拌时间为5-10分钟，每次紫外照射时间为3-5分钟，获得抑菌抗病毒中药微胶囊。
2.抑菌抗病毒中药微胶囊，其特征在于，利用权利要求1所述的方法制备获得的PMMA胶囊保护的中药粉体微粒。
3.抑菌抗病毒PVC热收缩标签膜的制备方法，其特征在于，将PVC树脂、热稳定剂、增塑剂、加工助剂、增强剂、内润滑剂、外润滑剂和抑菌抗病毒助剂混合，并经过挤出机塑化、吹膜机头成型、风环冷却、第一膜泡、二次加热、二次吹胀、冷却定型，抑菌抗病毒PVC热收缩标签膜，所述抑菌抗病毒助剂为权利要求2所述的抑菌抗病毒中药微胶囊。
4.根据权利要求3所述的抑菌抗病毒PVC热收缩标签膜的制备方法，其特征在于，按质量份计，PVC树脂100份、热稳定剂2份、增塑剂4.5份、加工助剂2份、增强剂4份、内润滑剂1.2份、外润滑剂0.8份和权利要求2所述的抑菌抗病毒中药微胶囊3-5份。
5.抑菌抗病毒PVC热收缩标签膜，其特征在于，利用权利要求3或4的方法制备的具有抑菌抗病毒性能的PVC热收缩标签膜。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210358111.4A CN114586779B (zh) | 2022-04-07 | 2022-04-07 | 抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒pvc热收缩标签膜及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210358111.4A CN114586779B (zh) | 2022-04-07 | 2022-04-07 | 抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒pvc热收缩标签膜及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114586779A CN114586779A (zh) | 2022-06-07 |
| CN114586779B true CN114586779B (zh) | 2023-10-24 |
Family
ID=81812811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210358111.4A Active CN114586779B (zh) | 2022-04-07 | 2022-04-07 | 抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒pvc热收缩标签膜及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114586779B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104746350A (zh) * | 2015-03-13 | 2015-07-01 | 常州大学 | 一种含中药油微胶囊的聚丙烯酸酯粘合剂及其制备方法和应用 |
| CN109320877A (zh) * | 2018-10-17 | 2019-02-12 | 宜兴市光辉包装材料有限公司 | 一种抗菌pvc热收缩标签膜及其制备方法 |
| CN111996801A (zh) * | 2020-08-19 | 2020-11-27 | 绍兴德美新材料有限公司 | 一种环保抗菌型硬挺剂及其制备方法 |
-
2022
- 2022-04-07 CN CN202210358111.4A patent/CN114586779B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104746350A (zh) * | 2015-03-13 | 2015-07-01 | 常州大学 | 一种含中药油微胶囊的聚丙烯酸酯粘合剂及其制备方法和应用 |
| CN109320877A (zh) * | 2018-10-17 | 2019-02-12 | 宜兴市光辉包装材料有限公司 | 一种抗菌pvc热收缩标签膜及其制备方法 |
| CN111996801A (zh) * | 2020-08-19 | 2020-11-27 | 绍兴德美新材料有限公司 | 一种环保抗菌型硬挺剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114586779A (zh) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saraswathi et al. | Phytoremediation of dyes using Lagerstroemia speciosa mediated silver nanoparticles and its biofilm activity against clinical strains Pseudomonas aeruginosa | |
| Mushore et al. | Antibacterial properties of Mangifera indica on Staphylococcus aureus | |
| Zhao et al. | Biosynthesis of copper nanoparticles using Allium eriophyllum Boiss leaf aqueous extract; characterization and analysis of their antimicrobial and cutaneous wound‐healing potentials | |
| Gorbunova et al. | Alginate-based encapsulation of extracts from beta Vulgaris cv. beet greens: Stability and controlled release under simulated gastrointestinal conditions | |
| Zangeneh | Green synthesis and chemical characterization of silver nanoparticles from aqueous extract of Falcaria vulgaris leaves and assessment of their cytotoxicity and antioxidant, antibacterial, antifungal and cutaneous wound healing properties | |
| Gasti et al. | Physicochemical and biological evaluation of different extracts of edible Solanum nigrum L. leaves incorporated chitosan/poly (vinyl alcohol) composite films | |
| WO2014179305A1 (en) | Soap composition | |
| CN101818005A (zh) | 一种防菌抑菌uv胶印油墨 | |
| CN104490716B (zh) | 一种化妆品防腐用组合物及其应用 | |
| CN103601959A (zh) | 一种高透明聚烯烃塑料用纳米银无机抗菌母粒及其制备方法与它的用途 | |
| CN114586779B (zh) | 抑菌抗病毒中药微胶囊及其制备方法、抑菌抗病毒pvc热收缩标签膜及其制备方法 | |
| Yadav et al. | Screening of In-vitro anti-inflammatory and Antifungal assay of Psidium guajava Leaf Extracts | |
| Bahattab et al. | Synthesis and biological activities of alcohol extract of black cumin seeds (Bunium persicum)-based gold nanoparticles and their catalytic applications | |
| CN106821935A (zh) | 从鲎试剂废料中提取抑菌组合物制备化妆品的方法 | |
| KR101968316B1 (ko) | 생분해성 고분자 플라스틱을 함유하는 의료용기 | |
| Liu et al. | Preparation, physicochemical and biological evaluation of chitosan Pleurotus ostreatus polysaccharides active films for food packaging | |
| CN105028067B (zh) | 一种防治黄萎病的方法 | |
| Madhavan et al. | Murraya koenigii extract blended nanocellulose-polyethylene glycol thin films for the sustainable synthesis of antibacterial food packaging | |
| Cui et al. | Novel design and combination strategy of minocycline and OECs-loaded CeO2 nanoparticles with SF for the treatment of spinal cord injury: In vitro and in vivo evaluations | |
| CN1247186C (zh) | 皮肤护理液 | |
| CN110433134A (zh) | 一种释放一氧化氮软膏及其制备方法与应用 | |
| CN114988987A (zh) | 一种桃柁酚的提取方法 | |
| FR2530467A1 (fr) | Element distributeur progressif de substances actives, son procede de fabrication et composition pour sa fabrication | |
| Guo et al. | Synthesis, applications in therapeutics, and bioimaging of traditional Chinese medicine-derived carbon dots | |
| Wang et al. | Biogenic preparation of copper oxide nanoparticles using table olive: Catalytic reduction, cytotoxicity, and burn wound healing activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |